Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in Prog Urol

Retrieve available abstracts of 61 articles:
HTML format



Single Articles


    June 2020
  1. PERCOT M, Robert G, Bladou F, Ferriere JM, et al
    Active surveillance in prostate cancer is possible for Afro-Caribbean population: Comparison of oncological outcomes with a Caucasian cohort.
    Prog Urol. 2020 Jun 24. pii: S1166-7087(20)30185.
    PubMed     Abstract available


  2. ROZET F, Hennequin C, Beuzeboc P, Mathieu R, et al
    [French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020].
    Prog Urol. 2020 Jun 6. pii: S1166-7087(20)30139.
    PubMed     Abstract available


    May 2020
  3. TEAN O, Bras Da Silva C, Vega Toro P, Barre P, et al
    [Epidemiology of prostate cancer (PCa) in French Guyana (FG) - Preliminary results].
    Prog Urol. 2020 May 31. pii: S1166-7087(20)30167.
    PubMed     Abstract available


  4. LE PAIH JP, Bladou F, Klein C, Rouget B, et al
    [Predictive factors of active surveillance interruption for prostate cancer after 5years of follow-up].
    Prog Urol. 2020 May 29. pii: S1166-7087(20)30135.
    PubMed     Abstract available


    April 2020
  5. MORERE JF, Touboul C, Lhomel C, Roupret M, et al
    [Prostate cancer screening in France: Results from the EDIFICE surveys].
    Prog Urol. 2020 Apr 21. pii: S1166-7087(20)30096.
    PubMed     Abstract available


    March 2020
  6. VILLERS A, Bessaoud F, Tretarre B, Grosclaude P, et al
    Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Prog Urol. 2020 Mar 17. pii: S1166-7087(20)30056.
    PubMed     Abstract available


    February 2020
  7. PLANTE G, Bories PN, Denjean L, Pigat N, et al
    [TMPRSS2-Erg/AR-V7: Prognostic value of tests in urine and biopsy rince material in prostate cancer].
    Prog Urol. 2020 Feb 29. pii: S1166-7087(20)30028.
    PubMed     Abstract available


    December 2019
  8. GAULLIER M, Tricard T, Garnon J, Cazzato RL, et al
    [Percutaneous MR-guided prostate cancer cryoablation: Predictive factors and oncologic outcomes].
    Prog Urol. 2019 Dec 11. pii: S1166-7087(19)30605.
    PubMed     Abstract available


  9. BARDET F, Frontczak A, Schneider A, Delattre B, et al
    [Prostate MRI and screening: Practice survey with general practitioner of the "Bourgogne-Franche Comte" region].
    Prog Urol. 2019;29:974-980.
    PubMed     Abstract available


  10. DUQUESNE I, Champy C, Klap J, Chahwan C, et al
    [When to introduce hormone therapy after total prostatectomy with positive lymph nodes? Study of the factors influencing the time of introduction of hormone therapy].
    Prog Urol. 2019;29:981-988.
    PubMed     Abstract available


    November 2019
  11. TANGUY-MELAC A, Lesuffleur T, Fagot-Campagna A, Gastaldi-Menager C, et al
    Health care utilization by men with prostate cancer during the year before their death: A 2015 population-based study.
    Prog Urol. 2019 Nov 7. pii: S1166-7087(19)30540.
    PubMed     Abstract available


  12. MONGIAT-ARTUS P, Paillaud E, Caillet P, Albrand G, et al
    [Geriatric specificities of prostate cancer].
    Prog Urol. 2019;29:828-839.
    PubMed     Abstract available


    October 2019
  13. BASTIE JP, Game X, Roumiguie M
    [Key points of the announcement for metastatic prostate cancer].
    Prog Urol. 2019 Oct 20. pii: S1166-7087(19)30544.
    PubMed     Abstract available


  14. VENI T, Leroy V, Pradere B, Rebillard A, et al
    [Patients with prostate cancer treated by androgen deprivation therapy: Impact of adapted physical activity].
    Prog Urol. 2019 Oct 18. pii: S1166-7087(19)30539.
    PubMed     Abstract available


  15. THOMAS L, Lacarriere E, Martinache G, Martinache PR, et al
    [Experience of day case robotic prostatectomy. About thirty-two patients].
    Prog Urol. 2019;29:619-626.
    PubMed     Abstract available


    August 2019
  16. AOUN F, Albisinni S, Biaou I, Peltier A, et al
    Salvage Hemiablation High Intensity Focused Ultrasound for unilateral radio-recurrent prostate cancer.
    Prog Urol. 2019 Aug 7. pii: S1166-7087(19)30155.
    PubMed     Abstract available


    July 2019
  17. VALLAT A, Pillot P, Lebacle C, Irani J, et al
    [Prognostic value of testosterone during androgene deprivation therapy].
    Prog Urol. 2019 Jul 13. pii: S1166-7087(19)30153.
    PubMed     Abstract available


  18. ANDRIANNE R
    The "Mini-Jupette" sling at the time of inflatable penile prosthesis implantation: Adequate treatment for erectile dysfunction with mild incontinence and/or climacturia after radical prostatectomy.
    Prog Urol. 2019 Jul 9. pii: S1166-7087(19)30112.
    PubMed     Abstract available


  19. ROSE DITE MODESTINE J, Neuzillet Y, Herve JM, Bosset PO, et al
    [12-year history of radical surgery indications for the treatment of prostate cancer].
    Prog Urol. 2019 Jul 4. pii: S1166-7087(19)30157.
    PubMed     Abstract available


    June 2019
  20. KLEINCLAUSS F, Frontczak A, Balssa L, Lebdai S, et al
    [Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].
    Prog Urol. 2019 Jun 29. pii: S1166-7087(19)30113.
    PubMed     Abstract available


  21. HENNEQUIN C
    [Toxicity of multimodal regimens in prostate cancer].
    Prog Urol. 2019;29 Suppl 1:S35-S41.
    PubMed     Abstract available


  22. KLEINCLAUSS F, Thiery-VuiUemin A
    [Oligometastatic prostate cancer management].
    Prog Urol. 2019;29 Suppl 1:S20-S34.
    PubMed     Abstract available


  23. ERRA B, Pradere B
    [Nuclear medicine for prostate cancer management].
    Prog Urol. 2019;29 Suppl 1:S2-S7.
    PubMed     Abstract available


  24. LATORZEFF I
    [Optimizing local control of high-risk prostate cancers through multimodal treatments].
    Prog Urol. 2019;29 Suppl 1:S8-S19.
    PubMed     Abstract available


  25. HOUEDE N
    [Management of patients with systemic treatments].
    Prog Urol. 2019;29 Suppl 1:S42-S50.
    PubMed     Abstract available


  26. BRUYERE F

    Prog Urol. 2019;29 Suppl 1:S1.
    PubMed    


    January 2019
  27. DELPORTE G, Olivier J, Ruffion A, Crouzet S, et al
    [Evolution of the number of incident cases, stage and first treatments for prostate cancer in France between 2001 and 2016].
    Prog Urol. 2019 Jan 8. pii: S1166-7087(18)30684.
    PubMed     Abstract available


    December 2018
  28. MOUREAUX C, Boucaud-Maitre D, Brureau L, Gourtaud G, et al
    [Pelvimetrics measures as predictives factors of positives surgical margins after robot-assisted laparoscopic prostatectomy].
    Prog Urol. 2018;28:906-914.
    PubMed     Abstract available


  29. THEVENIAUD PE, Zafar N, Hajj AE, Germain A, et al
    Mid term functional results following surgical treatment of recto-urinary fistulas postprostate cancer treatment.
    Prog Urol. 2018;28:915-920.
    PubMed     Abstract available


    November 2018
  30. ROZET F, Hennequin C, Beauval JB, Beuzeboc P, et al
    [French ccAFU guidelines - Update 2018-2020: Prostate cancer].
    Prog Urol. 2018 Nov 1. pii: S1166-7087(18)30514.
    PubMed     Abstract available


    October 2018
  31. PATARD PM, Roumiguie M, Prudhomme T, Doumerc N, et al
    Migration in last decade to high-risk prostate cancer after radical prostatectomy.
    Prog Urol. 2018 Oct 15. pii: S1166-7087(18)30557.
    PubMed     Abstract available


  32. ARNOUIL N, Gelet A, Matillon X, Rouviere O, et al
    [Focal HIFU vs robot-assisted total prostatectomy: Functionnal and oncologic outcomes at one year].
    Prog Urol. 2018;28:603-610.
    PubMed     Abstract available


    September 2018
  33. DELPORTE G, Henon F, Ploussard G, Briganti A, et al
    Radical prostatectomy for locally advanced and high-risk prostate cancer: A systematic review of the literature.
    Prog Urol. 2018 Sep 24. pii: S1166-7087(18)30472.
    PubMed     Abstract available


  34. AOUN F, Slaoui A, Walid EHO, Albisinni S, et al
    Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
    Prog Urol. 2018 Sep 7. pii: S1166-7087(18)30182.
    PubMed     Abstract available


  35. MEUNIER ME, Neuzillet Y, Radulescu C, Cherbonnier C, et al
    [Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence?]
    Prog Urol. 2018;28:475-481.
    PubMed     Abstract available


    June 2018
  36. GURY L, Robert G, Bensadoun H
    [Where do we stand with benign prostatic hyperplasia day-case surgery: A laser effect?]
    Prog Urol. 2018 Jun 12. pii: S1166-7087(18)30121.
    PubMed     Abstract available


  37. BRUREAU L, Emeville E, Multigner L, Blanchet P, et al
    Predictors of biochemical recurrence after radical prostatectomy in an Afro-Caribbean population in Guadeloupe (French West Indies).
    Prog Urol. 2018;28.
    PubMed     Abstract available


  38. ALBISINNI S, Grosman J, Aoun F, Quackels T, et al
    Exploring positive surgical margins after minimally invasive radical prostatectomy: Does body habitus really make a difference ?
    Prog Urol. 2018;28.
    PubMed     Abstract available


    May 2018
  39. RAICHI A, Marcq G, Fantoni JC, Puech P, et al
    [Active surveillance in prostate cancer: Assessment of MRI in the selection and follow-up of patients].
    Prog Urol. 2018 May 31. pii: S1166-7087(18)30085.
    PubMed     Abstract available


  40. HACHI K, Boualga K, Chettibi K, Harouni M, et al
    [Study of the beneficial effects of triptorelin on lower urinary tract symptoms in Algeria in patients with non-localized prostate cancer].
    Prog Urol. 2018 May 20. pii: S1166-7087(18)30094.
    PubMed     Abstract available


  41. MARTIN-MALBURET A, Marcq G, Leroy X, Guiffart P, et al
    [Pathology findings after radical prostatectomy for prostate cancer in patients eligible for active surveillance: Contribution of multiparametric MRI to treatment decision].
    Prog Urol. 2018 May 20. pii: S1166-7087(18)30092.
    PubMed     Abstract available


    April 2018
  42. ROZET F, Hennequin C, Mongiat-Artus P, Beuzeboc P, et al
    [French CCAFU guidelines on prostate cancer: hormono-naive metastatic prostate cancer - update 2017].
    Prog Urol. 2018 Apr 18. pii: S1166-7087(18)30080.
    PubMed    


    March 2018
  43. GEVORGYAN A, Hetet JF, Robert M, Duchattelle-Dussaule V, et al
    [Salvage cryotherapy of prostate cancer after failed external radiotherapy and brachytherapy: Morbidity and mid-term oncological results].
    Prog Urol. 2018 Mar 15. pii: S1166-7087(17)30543.
    PubMed     Abstract available


    February 2018
  44. SARRADIN M, Lepiney C, Celhay O, Delpech PO, et al
    [Estimating minimum period of time to perform prostate MRI after prostate biopsy: Clinical and histological bleeding risk factors; from a prospective study].
    Prog Urol. 2018;28:85-93.
    PubMed     Abstract available


    January 2018
  45. ALBISINNI S, Aoun F, Noel A, El Rassy E, et al
    Are concurrent systematic cores needed at the time of targeted biopsy in patients with prior negative prostate biopsies?
    Prog Urol. 2018;28:18-24.
    PubMed     Abstract available


    December 2017
  46. DE LA TAILLE A, Mardoyan S, Lafaye A
    [Psychological impact of prostate cancer on patients receiving a 6-month androgen deprivation therapy].
    Prog Urol. 2017 Dec 6. pii: S1166-7087(17)30625.
    PubMed     Abstract available


  47. DE VERGIE S, Gaschignard N, Baron M, Branchereau J, et al
    [Long-term outcomes of prostate cancer patients with lymph nodes metastasis after radical prostatectomy and pelvic lymph node dissection].
    Prog Urol. 2017 Dec 5. pii: S1166-7087(17)30624.
    PubMed     Abstract available


    November 2017
  48. DEFONTAINES J, Salomon L, Champy C, Cholley I, et al
    [Prostate cancer diagnostic by saturation randomized biopsy versus rigid targeted biopsy].
    Prog Urol. 2017 Nov 6. pii: S1166-7087(17)30536.
    PubMed     Abstract available


    September 2017
  49. RENARD-PENNA R, Sanchez-Salas R, Barret E, Cosset JM, et al
    [Evaluation and results of ablative therapies in prostate cancer].
    Prog Urol. 2017 Sep 19. pii: S1166-7087(17)30455.
    PubMed     Abstract available


  50. BARRET E, Sanchez-Salas R, Galiano M, Cathala N, et al
    [Management of ablative therapies in prostate cancer].
    Prog Urol. 2017 Sep 14. pii: S1166-7087(17)30411.
    PubMed     Abstract available


  51. SANCHEZ-SALAS R, Barret E, Renard-Penna R, Cosset JM, et al
    [Indications and limits of ablative therapies in prostate cancer].
    Prog Urol. 2017 Sep 14. pii: S1166-7087(17)30456.
    PubMed     Abstract available


    June 2017
  52. MARIEN A, De Castro Abreu A, Gill I, Villers A, et al
    [Interest using 3D ultrasound and MRI fusion biopsy for prostate cancer detection].
    Prog Urol. 2017 Jun 16. pii: S1166-7087(17)30130.
    PubMed     Abstract available


    May 2017
  53. VIDMAR R, Marcq G, Flamand V, Fantoni JC, et al
    [Salvage radical prostatectomy for recurrent prostate cancer. Morbidity, oncological and functional results].
    Prog Urol. 2017 May 30. pii: S1166-7087(17)30108.
    PubMed     Abstract available


  54. GIRIER D, Chevrot A, Costa P, Thuret R, et al
    [Sexual consequences after treatment of prostate cancer: Inquiry among members of the Association Nationale des Malades du Cancer de la Prostate].
    Prog Urol. 2017 May 5. pii: S1166-7087(17)30075.
    PubMed     Abstract available


    April 2017
  55. MONDET F, Alimi JC, Boyer C
    [Cancer plans apply to surgical treatment of prostate cancer: A geographically isolated center balance].
    Prog Urol. 2017 Apr 6. pii: S1166-7087(17)30046.
    PubMed     Abstract available


  56. ROZET F, Roupret M, Hennequin C, Massard C, et al
    [Management of a progressing prostate cancer: results of a national study].
    Prog Urol. 2017 Apr 6. pii: S1166-7087(17)30022.
    PubMed     Abstract available


    March 2017
  57. LONG JA, Poinas G, Fiard G, Lepretre M, et al
    [Robot assisted radical prostatectomy: What are the evidences at the time of a specific funding?]
    Prog Urol. 2017;27:146-157.
    PubMed     Abstract available


  58. LIMANI K, Albisinni S, Aoun F, Le Dinh D, et al
    [Quality of life after robotic prostatectomy: Impact of BMI and age on urinary incontinence].
    Prog Urol. 2017;27:244-252.
    PubMed     Abstract available


    November 2016
  59. COHEN J, Andre C, Mozer P
    [Targeted MRI prostate biopsies].
    Prog Urol. 2016;26:854-859.
    PubMed     Abstract available


    July 2016
  60. RIOUX-LECLERCQ N, Comperat E, Kammerer-Jacquet SF, Camparo P, et al
    [Pathological advances in renal, prostatic, bladder and testis neoplasia].
    Prog Urol. 2016 Jul 26. pii: S1166-7087(16)30070.
    PubMed     Abstract available


    May 2016
  61. BARRE C, Nguyen JM
    [Addendum concerning: "A prospective trial comparing consecutive series of open retropubic and robot-assisted laparoscopic radical prostatectomy in a centre: Oncologic and functional outcomes" written by J.B. Beauval et al. [Prog. Urol. 25 (2015) 370-
    Prog Urol. 2016;26:383-4.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: